ClinicalTrials.gg
CompletedNCT04749641ENACTINGUpdated Jun 6, 2025

Neoantigen Vaccine Therapy Against H3.3-K27M Diffuse Intrinsic Pontine Glioma

A Phase 1 interventional study of Histone H3.3-K27M Neoantigen Vaccine Therapy in Diffuse Intrinsic Pontine Glioma, sponsored by Yang Zhang. Completed at 1 site in China. Open to participants aged 5 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-06-06.

Sponsored by Yang Zhang · Phase 1, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
16
Allocation
Non-randomized
Ages
5 Years and older
Sex
All
01

Study summary

Diffuse intrinsic pontine gliomas (DIPGs), which diffusely occupy the pons of brainstem, are the deadliest primary brain cancer in children. Biopsy for pathology plus radiotherapy remains the current standard-of-care treatment that is minimal effective. Thus, the median overall survival after diagnosis is just 10 months. Recent studies have identified a lysine 27-to-methionine (K27M) somatic mutation at histone H3 variant (H3.3), as a feature mutation in DIPGs. Several preclinical studies have already demonstrated H3.3-K27M as a promising target for immunotherapy. The researched vaccine is a cancer-treatment vaccine containing an H3.3-K27M targeted neoantigen peptide, that can be taken up by antigen-presenting cells (APCs). APCs can present the peptide with the major histocompatibility complex (MHC) molecules on cell surface, thereby activating neoantigen-specific T cells and triggering corresponding cytotoxic T cell immune responses to eliminate H3.3-K27M-expressing DIPG cells. The main goal of this study is investigating the safety and preliminary efficacy of the vaccine in treating newly-diagnosed DIPGs when the vaccine is administered in combination with the standard-of-care treatment.

02

Conditions studied

  • Diffuse Intrinsic Pontine Glioma
03

In context

Diffuse Intrinsic Pontine Glioma

119 studies on the registry are indexed under Diffuse Intrinsic Pontine Glioma; 38 are open to participants now.

This study's enrollment of 16 is below the median of 30 across 109 interventional studies indexed under Diffuse Intrinsic Pontine Glioma.

Browse Diffuse Intrinsic Pontine Glioma studies →

Lead sponsor

Yang Zhang is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
5 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

A. First entry criteria

  1. Age ≥ 5 years old;
  2. Newly-diagnosed patients with DIPG appearance on MRI image;
  3. HLA-A2 subtype;
  4. The expected survival time exceeds 24 weeks;
  5. The score is greater than 50; B. Second entry criteria
  1. The KPS score is greater than 50; 2. DIPG is diagnosed histologically on tumor tissue obtained by or surgical resection; 3. H3.3K27M mutation is detected on tumor tissue obtained by biopsy or surgical resection ; 4. Adequate organ functions that meet the following criteria: The absolute number of neutrophils: ≥1500/mm3 count: ≥75000/uL : ≥80 g/L Creatinine≤1.5× ≤1.5×ULN ≤3×ULN AST≤3×ULN 5. Ability to comprehend and sign an form.

Exclusion criteria

Exclusion Criteria:

  1. With past medical history of malignant tumors (except being asymptomatic for more than 3 years);
  2. History of allergy to chemotherapeutics or radiosensitizers for the treatment of cancer in central nervous system and head/neck;
  3. History of allergy to the vaccine and its ingredients;
  4. Comorbidity with infection and/or acute phase of /C;
  5. Any progressive diseases that hinder participation in the trial;
  6. With unstable cardiovascular diseases such as coronary heart disease, angina pectoris, myocardial infarction, arrhythmia et.al.;
  7. History of uncontrolled mental illnesses;
  8. Inability to comprehend or sign form or abide by the research procedures;
  9. Other conditions believed to hinder participation in this trial at investigator' discretion.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
16 participants (actual)

Study arms

  • Experimental
    Open surgical biopsy

    A total of 15 subjects with open surgical biopsy indications will receive microsurgical resection, followed by conformal radiotherapy and administration of the researched vaccine.

    Biological: Histone H3.3-K27M Neoantigen Vaccine Therapy

  • Experimental
    Stereotactic biopsy

    A total of 15 subjects without open surgical biopsy indications will receive stereotactic biopsy, followed by conformal radiotherapy and administration of the researched vaccine.

    Biological: Histone H3.3-K27M Neoantigen Vaccine Therapy

Interventions

  • BiologicalHistone H3.3-K27M Neoantigen Vaccine Therapy

    The researched vaccine, containing H3.3-K27M-targeting neoantigen peptides and poly ICLC, will be administered through subcutaneous injection into DIPG patients after they complete surgical/stereotactic biopsy and conformal radiotherapy. The day of first vaccine injection is defined as D1 (day 1), and then the injections will be administered on D3, D15, Day 29, Day 57, Day 85 and one injection every 8 weeks thereafter. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a "6+3" dose escalation design is applied. There are three doses for the vaccine. Dose 1: 0.5mg peptide + Poly ICLC; Dose 2: 1mg peptide + Poly ICLC; Dose 3: 2mg peptide + Poly ICLC.

06

What researchers measure

Primary outcomes

  1. Safety of histone H3.3-K27M neoantigen vaccine in treating newly diagnosed DIPGs

    AEs were graded according to the Common Terminology Criteria for Adverse Events (CTCAE) version 4.03.

    Time frame: All the Adverse events (AEs) were recorded until 24 weeks after the last shot

  2. Rate of the patients who survive for more than one year after surgery/biopsy in all the DIPG patients who receive H3.3-K27M neoantigen vaccine

    One-year survival rate

    Time frame: One year after surgery or biopsy

Secondary outcomes

  1. Maximum Tolerated Dose of H3.3-K27M neoantigen vaccine to treat DIPGs

    "\>= Grade 3 " vaccine related AEs are defined as DLTs. In order to determine the Maximum Tolerated Dose (MTD) of the vaccine, a "6+3" dose escalation design is applied.

    Time frame: DLTs were monitored at timepoints of every vaccine shot until the 28th day after the first injection

  2. Rate of the patients who survive for more than two years after surgery/biopsy in all the DIPG patients who receive H3.3-K27M neoantigen vaccine

    two-year survival rate

    Time frame: two years after surgery or biopsy

  3. Median Progression-free survival time of the DIPG patients who receive H3.3-K27M neoantigen vaccine

    Progression-free survival time: the time from operation/biopsy to progression (when shows signs or symptoms of the growth or the spreading of a tumor)

    Time frame: start 4 weeks after the first shot and every 8 weeks until disease progression

  4. Median Overall survival time of the DIPG patients who receive H3.3-K27M neoantigen vaccine

    overall survival time: the time from operation/biopsy to death.

    Time frame: start 4 weeks after the first shot and every 8 weeks until death

  5. Immunological effectiveness of H3.3-K27M neoantigen vaccine for the treatment of DIPG patients

    Immunological effectiveness is measured by an IFN-γ ELISPOT assay as number of spot-forming cells in one million peripheral blood mononuclear cells.

    Time frame: baseline 1: pre-radiotherapy; baseline 2: immediately after completing radiotherapy; Day 15, Day 57, Day 85 and every 8 weeks thereafter until up to 2 years after the first shot.

07

Study locations

1 site
  • Beijing Tiantan Hospital, Capital Medical University
    Beijing, Beijing 100070, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2021 to primary completion in Oct 2024, 43 months.

Of 35 non-industry phase 1 interventional studies under Diffuse Intrinsic Pontine Glioma, half reached primary completion within 67 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 92. This study's 43 months is below that.

Counting every sponsor, half of 37 studies reached it within 67 months; a quarter within 40 and three quarters within 100.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2021
First posted
Feb 11, 2021
StartActual
Mar 8, 2021
Primary completionActual
Oct 14, 2024
CompletionActual
Oct 14, 2024
Last update
Jun 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04749641
Lead sponsor
Yang Zhang
Collaborators
TCRCure Biopharma Ltd.
Responsible party
Yang Zhang (Department of Neurosurgery, Beijing Tiantan Hospital, Capital Medical University, No.119 South Fourth Ring West Road, Fengtai District, Beijing,100070 P.R.China, Beijing Tiantan Hospital) — Sponsor-investigator
First posted
Feb 11, 2021
Start date
Mar 8, 2021
Primary completion
Oct 14, 2024
Completion
Oct 14, 2024
Last update
Jun 6, 2025

Study contacts

Liwei Zhang, M.D.
principal investigator · Beijing Tiantan Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion